Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.
NCT ID: NCT02174731
Last Updated: 2019-12-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
2133 participants
INTERVENTIONAL
2014-07-01
2018-09-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Roxadustat
Roxadustat
Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
Epoetin alfa
Epoetin alfa
Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Roxadustat
Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
Epoetin alfa
Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥18 years at screening visit 1
3. Previous versions of the protocol prior to US amendment ver 6.0 and outside of US amendment ver 7.0:
Receiving or initiating hemodialysis or peritoneal dialysis for treatment of native kidney end-stage renal disease (ESRD) at least 30 days prior to visit 1. Patients treated with hemodialysis must have access consisting of an arteriovenous fistula, AV graft, or tunneled (permanent) catheter. Patients on peritoneal dialysis must have a functioning peritoneal dialysis catheter in place.
Starting with US amendment ver. 6.0 and outside of US amendment ver 7.0 (changed to recruit incident dialysis patients only):
Receiving or initiating hemodialysis or peritoneal dialysis for treatment of native kidney end-stage renal disease (ESRD) for a minimum of 2 weeks and a maximum of 4 months prior to randomization. Patients treated with hemodialysis must have access consisting of an arteriovenous fistula, AV graft, or tunneled (permanent) catheter. Patients on peritoneal dialysis must have a functioning peritoneal dialysis catheter in place.
4. Two central laboratory Hb values during the screening period, obtained at least 7 days apart, must be \<12 g/dL in patients currently treated with an erythropoietin analogue or \<10 g/dL in patients not currently treated with an erythropoietin analogue. Patients are considered not currently treated if they have not received either Mircera® for at least 8 weeks or any other erythropoietin analogue for at least 4 weeks prior to visit 1.
5. Ferritin ≥100 ng/mL at randomization (obtained from screening visit)
6. TSAT ≥20% at randomization (obtained from screening visit)
7. Serum folate level ≥ lower limit of normal (LLN) at randomization (obtained from screening visit)
8. Serum vitamin B12 level ≥ LLN at randomization (obtained from screening visit)
9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3x upper limit of normal (ULN), and total bilirubin (Tbili) ≤1.5 x ULN at randomization (obtained from screening visit)
10. Body weight 45 to 160 kg (prescribed dry weight)
Exclusion Criteria
2. Previous randomisation in the present study
3. New York Heart Association Class III or IV congestive heart failure at enrolment
4. Myocardial infarction, acute coronary syndrome, stroke, seizure or a thrombotic/thromboembolic event (e.g., deep vein thrombosis or pulmonary embolism) within 12 weeks prior to randomization
5. History of chronic liver disease (e.g., chronic infectious hepatitis, chronic auto-immune liver disease, cirrhosis or fibrosis of the liver)
6. Known hereditary hematologic disease such as thalassemia, sickle cell anemia, a history of pure red cell aplasia or other known causes for anemia other than CKD
7. Known and untreated retinal vein occlusion or known and untreated proliferative diabetic retinopathy (risk for retinal vein thrombosis)
8. Diagnosis or suspicion (e.g. complex kidney cyst of Bosniak Category IIF, III or IV) of renal cell carcinoma on renal ultrasound (or other imaging procedure e.g. CT scan or MRI) conducted at screening or within 12 weeks prior to randomization.
9. Uncontrolled hypertension at the time of randomization (defined as systolic BP ≥180 mmHg or diastolic BP ≥100 mmHg on repeated measurement post-dialysis in hemodialysis patients or at any time in peritoneal dialysis patients), contraindication to epoetin alfa treatment (e.g., pure red cell aplasia, hypersensitivity or know inability to tolerate epoetin alfa)
10. History of prostate cancer, breast cancer or any other malignancy, except the following: cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ or resected colonic polyps.
11. Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus antibody (anti-HCV Ab)
12. Chronic inflammatory diseases such as rheumatoid arthritis, SLE, ankylosing spondylitis, psoriatic arthritis or inflammatory bowel disease that is determined to be the principal cause of anemia
13. Known hemosiderosis, hemochromatosis or hypercoagulable condition
14. Any prior organ transplant with the exception of an autologous renal transplant or a renal transplant that was subsequently removed ("explanted") or scheduled organ transplantation date
15. Any red blood cell (RBC) transfusion during the screening period
16. Any current condition leading to active significant blood loss
17. Any prior treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)
18. Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within the month preceding the first administration of IP in this study. (Note: patients consented and screened, but not randomized in this study or a previous study are not excluded)
19. History of alcohol or drug abuse within 2 years prior to randomization
20. Females of childbearing potential, unless using contraception as detailed in the protocol or sexual abstinence (see Section 3.8)
21. Pregnant or breastfeeding females
22. Known allergy to the investigational product or any of its ingredients
23. Any medical condition, including active, clinically significant infection, that in the opinion of the investigator or Sponsor may pose a safety risk to a patient in this study, which may confound efficacy or safety assessment, or may interfere with study participation
18 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
FibroGen
INDUSTRY
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven Fishbane, MD
Role: PRINCIPAL_INVESTIGATOR
Chief Division of Kidney Diseases and Hypertension, North Shore University Hospital, Great Neck, NY, USA
Mark Houser, MD
Role: STUDY_DIRECTOR
AZ R&D, Gaithersburg, USA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Huntsville, Alabama, United States
Research Site
El Centro, California, United States
Research Site
Fairfield, California, United States
Research Site
Glendale, California, United States
Research Site
Long Beach, California, United States
Research Site
Long Beach, California, United States
Research Site
Los Angeles, California, United States
Research Site
Los Angeles, California, United States
Research Site
Lynwood, California, United States
Research Site
Northridge, California, United States
Research Site
Ontario, California, United States
Research Site
Orange, California, United States
Research Site
Riverside, California, United States
Research Site
Sacramento, California, United States
Research Site
Sun Valley, California, United States
Research Site
Whittier, California, United States
Research Site
Whittier, California, United States
Research Site
Denver, Colorado, United States
Research Site
New Haven, Connecticut, United States
Research Site
Miami Gardens, Florida, United States
Research Site
River Forest, Illinois, United States
Research Site
Wichita, Kansas, United States
Research Site
Baton Rouge, Louisiana, United States
Research Site
Lanham, Maryland, United States
Research Site
Plymouth, Massachusetts, United States
Research Site
Roseville, Michigan, United States
Research Site
Gulfport, Mississippi, United States
Research Site
Kansas City, Missouri, United States
Research Site
Reno, Nevada, United States
Research Site
Paterson, New Jersey, United States
Research Site
Great Neck, New York, United States
Research Site
Orchard Park, New York, United States
Research Site
The Bronx, New York, United States
Research Site
Asheville, North Carolina, United States
Research Site
Charlotte, North Carolina, United States
Research Site
Wilmington, North Carolina, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Shawnee, Oklahoma, United States
Research Site
Bethlehem, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
East Providence, Rhode Island, United States
Research Site
Austin, Texas, United States
Research Site
Austin, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Houston, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Newport News, Virginia, United States
Research Site
Sterling, Virginia, United States
Research Site
Bluefield, West Virginia, United States
Research Site
Camperdown, , Australia
Research Site
Clayton, , Australia
Research Site
Concord, , Australia
Research Site
Launceston, , Australia
Research Site
Prahan, , Australia
Research Site
St Leonards, , Australia
Research Site
Wahroonga, , Australia
Research Site
Botevgrad, , Bulgaria
Research Site
Dupnitsa, , Bulgaria
Research Site
Gotse Delchev, , Bulgaria
Research Site
Haskovo, , Bulgaria
Research Site
Razlog, , Bulgaria
Research Site
Samokov, , Bulgaria
Research Site
Sandanski, , Bulgaria
Research Site
Shumen, , Bulgaria
Research Site
Silistra, , Bulgaria
Research Site
Sliven, , Bulgaria
Research Site
Smolyan, , Bulgaria
Research Site
Yambol, , Bulgaria
Research Site
Edmonton, Alberta, Canada
Research Site
Kamloops, British Columbia, Canada
Research Site
Saint John, New Brunswick, Canada
Research Site
Sydney, Nova Scotia, Canada
Research Site
Brampton, Ontario, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Scarborough Village, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Greenfield Park, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Brno, , Czechia
Research Site
Prague, , Czechia
Research Site
Prague, , Czechia
Research Site
Prague, , Czechia
Research Site
Rychnov nad Kněžnou, , Czechia
Research Site
Slaný, , Czechia
Research Site
Tábor, , Czechia
Research Site
Ústí nad Labem, , Czechia
Research Site
Ajka, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Debrecen, , Hungary
Research Site
Miskolc, , Hungary
Research Site
Nagykanizsa, , Hungary
Research Site
Székesfehérvár, , Hungary
Research Site
Tatabánya, , Hungary
Research Site
Chennai, , India
Research Site
Ghaziabad NCR, , India
Research Site
Hyderabad, , India
Research Site
Kolkata, , India
Research Site
Lucknow, , India
Research Site
Maharashtra, , India
Research Site
Mumbai, , India
Research Site
Mysore, , India
Research Site
Nadiād, , India
Research Site
New Delhi, , India
Research Site
New Delhi, , India
Research Site
Pune, , India
Research Site
Vellore, , India
Research Site
Vijayawada, , India
Research Site
Aguascalientes, , Mexico
Research Site
Guadalajara, , Mexico
Research Site
México, , Mexico
Research Site
Veracruz, , Mexico
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Cebu City, , Philippines
Research Site
Iloilo City, , Philippines
Research Site
Ciechanów, , Poland
Research Site
Gmina Końskie, , Poland
Research Site
Katowice, , Poland
Research Site
Lodz, , Poland
Research Site
Lodz, , Poland
Research Site
Pszczyna, , Poland
Research Site
Suwałki, , Poland
Research Site
Tarnów, , Poland
Research Site
Warsaw, , Poland
Research Site
Arkhangelsk, , Russia
Research Site
Barnaul, , Russia
Research Site
Irkutsk, , Russia
Research Site
Izhevsk, , Russia
Research Site
Kemerovo, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Nizhny Novgorod, , Russia
Research Site
Penza, , Russia
Research Site
Perm, , Russia
Research Site
Pyatigorsk, , Russia
Research Site
Ryazan, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Ufa, , Russia
Research Site
Banská Bystrica, , Slovakia
Research Site
Banská Bystrica, , Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Košice, , Slovakia
Research Site
Kráľovský Chlmec, , Slovakia
Research Site
Nové Zámky, , Slovakia
Research Site
Zvolen, , Slovakia
Research Site
Almería, , Spain
Research Site
Barcelona, , Spain
Research Site
Granollers (Barcelona), , Spain
Research Site
Málaga, , Spain
Research Site
Seville, , Spain
Research Site
Seville, , Spain
Research Site
Tarragona, , Spain
Research Site
Valencia, , Spain
Research Site
Karlstad, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Uppsala, , Sweden
Research Site
Västerås, , Sweden
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Chernivtsi, , Ukraine
Research Site
Dnipro, , Ukraine
Research Site
Ivano-Frankivsk, , Ukraine
Research Site
Ivano-Frankivsk, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Odesa, , Ukraine
Research Site
Odesa, , Ukraine
Research Site
Poltava, , Ukraine
Research Site
Ternopil, , Ukraine
Research Site
Uzhhorod, , Ukraine
Research Site
Vinnytsia, , Ukraine
Research Site
Zaporizhzhya, , Ukraine
Research Site
Zaporizhzhya, , Ukraine
Research Site
Zaporizhzhya, , Ukraine
Research Site
Can Tho, , Vietnam
Research Site
Hanoi, , Vietnam
Research Site
Hochiminh, , Vietnam
Research Site
Huế, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hamano T, Yamaguchi Y, Goto K, Martin S, Jiletcovici A, Dellanna F, Akizawa T, Barratt J. Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials. Adv Ther. 2024 Apr;41(4):1553-1575. doi: 10.1007/s12325-023-02728-2. Epub 2024 Feb 16.
Barratt J, Dellanna F, Portoles J, Choukroun G, De Nicola L, Young J, Dimkovic N, Reusch M. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Adv Ther. 2023 Apr;40(4):1546-1559. doi: 10.1007/s12325-023-02433-0. Epub 2023 Feb 7.
Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.
Fishbane S, Pollock CA, El-Shahawy M, Escudero ET, Rastogi A, Van BP, Frison L, Houser M, Pola M, Little DJ, Guzman N, Pergola PE. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study. J Am Soc Nephrol. 2022 Apr;33(4):850-866. doi: 10.1681/ASN.2020111638.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5740C00002
Identifier Type: -
Identifier Source: org_study_id